acute respiratory distress syndrome (ards) therapeutics

1. Acute Respiratory Distress Syndrome (ARDS) Therapeutics - Pipeline Assessment and Market Forecasts to 2017

2. ARDS Therapeutics Market is Forecast to Show Slow Growth to 2017 GlobalData valued the global acute respiratory distress syndrome (ARDS) therapeutics market at $576.6m in 2010. The market is expected to grow at a compound annual growth rate (CAGR) of 2.4% to reach $682.6m in 2017. The steady growth is primarily attributed to the low incidence of the disease and a lack of approved drugs on the market. The competitive landscape currently consists of generic and offlabel drugs. Need for Approved and First-in-Class Drugs GlobalData’s research indicates that the ARDS pipeline is weak, with 12 molecules in the different phases of development. First-in-class molecules have distinct advantages over current drug treatment options in terms of disease management. The unmet need of the ARDS market is high as there are no approved drugs currently on the market. Treatment currently relies on off-label drugs such as Levaquin (levofloxacin), Nimbex (cisatracurium besylate) and generic drugs such as lorazepam and methylprednisolone. The market subsequently needs therapies offering better results in terms of safety and efficacy. Changing Future Landscape of the ARDS Market Altor BioScience Corporation, Faron Pharmaceuticals Ltd., Ikaria, Inc., and GlaxoSmithKline are going to be major players in the future ARDS market. GlobalData profiles these companies as they hold important pipeline ARDS drugs in Phase II.

3. The existing market landscape shows weak competition, due to the lack of approved drugs for the treatment of ARDS. The market is dominated by off-label treatment, such as Levaquin, Nimbex, and other generics such as methylprednisolone, clindamycin and lorazepam. The market scenario is expected to change with the launch of new therapies, such as tissue factor (TF) antagonists, CD modulators, p38 kinase inhibitors and DNA polymerase inhibitors. Weak Pipeline is Likely to Result in Slow Growth in the ARDS Market GlobalData analysis shows that the ARDS therapeutics pipeline is weak, with only 12 molecules in the different phases of development. Although there are eight first-in-class molecules, these are mostly in the early stages of development or in pre-clinical trials. Their impact on the market is subsequently not expected to be seen during the forecast period to 2017. There are currently no Phase III molecules in the pipeline. Consequently, the pipeline for the ARDS therapeutics market is weak and is not expected to greatly impact the market during the forecast period. For further details, please click or add the below link to your browser: http://www.globaldata.com/reportstore/Report.aspx?ID=Acute-Respiratory-Distress-Syndrome-%28ARDS%29-Therapeutics-Pipeline-Assessment-and-Market-Forecasts-to-2017&Title=Pharmaceuticals_and_Healthcare&ReportType=Industry_Report

4. GlobalData, the industry analysis specialist, has released its new report, “Acute Respiratory Distress Syndrome (ARDS) Therapeutics - Pipeline Assessment and Market Forecasts to 2017”. The report is an essential source of information and analysis on the global ARDS therapeutics market. The report identifies the key trends shaping and driving the global ARDS therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global ARDS therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts. Visit our report store: http://www.globaldata.com For more details contact: pressreleases@globaldata.com North America: +1 646 395 5477 Europe: +44 207 753 4299 +44 1204 543 533 Asia Pacific: +91 40 6616 6782